Comment from Advarra

Summary: Advarra, a clinical research organization, supports the FDA's draft guidance on using AI for regulatory decision-making, describing it as a "step in the right direction." They suggest specific improvements, including more detail on risk-based credibility assessments, the inclusion of MLOps/LLMOps best practices, and dedicated sections on data quality, synthetic data, and the distinction between explainability and interpretability.